(Q37289795)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author

Jean-Jacques Kiladjian

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Christine Chomienne

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

3

P Fenaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

9 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1990-1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843285%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2008.280

15 January 2020

exact match

0 references

cites work

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

Virus interference. I. The interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferons, interferon-like cytokines, and their receptors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

4 Production of interferon in human leukocytes from normal donors with the use of Sendai virus

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Isolation and structure of a human fibroblast interferon gene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Synthesis in E. coli of a polypeptide with human leukocyte interferon activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

The interferons: 50 years after their discovery, there is much more to learn

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Type I interferon receptors: biochemistry and biological functions.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Seeing the light: preassembly and ligand-induced changes of the interferon gamma receptor complex in cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Mechanisms of type-I- and type-II-interferon-mediated signalling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Stimulation of naïve and memory T cells by cytokines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Recombinant interferon-alpha for treatment of polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Treatment of essential thrombocythaemia by alpha 2a interferon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Alpha-interferon therapy for essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Recombinant interferon alpha-2b in the treatment of polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Recombinant alpha 2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon alpha-2b in the long-term treatment of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Recombinant interferon alpha-2b as treatment of essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Development of pegylated interferons for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon alpha in the treatment of polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Interferon-alpha in the treatment of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Polycythemia vera is not initiated by JAK2V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021

Pregnancy and its management in the Philadelphia negative myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.280

7 January 2021